|
1
|
Pui CH and Evans WE: Treatment of acute
lymphoblastic leukemia. N Engl J Med. 354:166–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Flotho C, Coustan-Smith E, Pei D, Cheng C,
Song G, Pui CH, Downing JR and Campana D: A set of genes that
regulate cell proliferation predicts treatment outcome in childhood
acute lymphoblastic leukemia. Blood. 110:1271–1277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jabeen K, Ashraf MS, Iftikhar S and
Belgaumi AF: The impact of socioeconomic factors on the outcome of
childhood acute lymphoblastic leukemia (ALL) treatment in a
low/middle income country (LMIC). J Pediatr Hematol Oncol.
38:587–596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dinmohamed AG, Szabó A, van der Mark M,
Visser O, Sonneveld P, Cornelissen JJ, Jongen-Lavrencic M and
Rijneveld AW: Improved survival in adult patients with acute
lymphoblastic leukemia in the Netherlands: A population-based study
on treatment, trial participation and survival. Leukemia.
30:310–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cruz-Rodriguez N, Combita AL, Enciso LJ,
Quijano SM, Pinzon PL, Lozano OC, Castillo JS, Li L, Bareño J,
Cardozo C, et al: High expression of ID family and IGJ genes
signature as predictor of low induction treatment response and
worst survival in adult Hispanic patients with B-acute
lymphoblastic leukemia. J Exp Clin Cancer Res. 35:642016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Es JH, Barker N and Clevers H: You Wnt
some, you lose some: Oncogenes in the Wnt signaling pathway. Curr
Opin Genet Dev. 13:28–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee HC, Kim M and Wands JR: Wnt/Frizzled
signaling in hepatocellular carcinoma. Front Biosci. 11:1901–1915.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim M, Lee HC, Tsedensodnom O, Hartley R,
Lim YS, Yu E, Merle P and Wands JR: Functional interaction between
Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin
signaling pathway in hepatocellular carcinoma cells. J Hepatol.
48:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei W, Chua MS, Grepper S and So SK:
Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes
hepatocellular carcinoma cells towards doxorubicin. Mol Cancer.
10:162011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reya T, Duncan AW, Ailles L, Domen J,
Scherer DC, Willert K, Hintz L, Nusse R and Weissman IL: A role for
Wnt signalling in self-renewal of haematopoietic stem cells.
Nature. 423:409–414. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weerkamp F, vanDongen JJ and Staal FJ:
Notch and Wnt signaling in T-lymphocyte development and acute
lymphoblastic leukemia. Leukemia. 20:1197–1205. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khan NI and Bendall LJ: Role of WNT
signaling in normal and malignant hematopoiesis. Histol
Histopathol. 21:761–774. 2006.PubMed/NCBI
|
|
13
|
Staal FJ and Clevers HC: WNT signalling
and haematopoiesis: A WNT-WNT situation. Nat Rev Immunol. 5:21–30.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Døsen G, Tenstad E, Nygren MK, Stubberud
H, Funderud S and Rian E: Wnt expression and canonical Wnt
signaling in human bone marrow B lymphopoiesis. BMC Immunol.
7:132006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Staal FJ and Sen JM: The canonical Wnt
signaling pathway plays an important role in lymphopoiesis and
hematopoiesis. Eur J Immunol. 38:1788–1794. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Timm A and Grosschedl R: Wnt signaling in
lymphopoiesis. Curr Top Microbiol Immunol. 290:225–252.
2005.PubMed/NCBI
|
|
17
|
Batra S, Shi Y, Kuchenbecker KM, He B,
Reguart N, Mikami I, You L, Xu Z, Lin YC, Clément G, et al: Wnt
inhibitory factor-1, a Wnt antagonist, is silenced by promoter
hypermethylation in malignant pleural mesothelioma. Biochem Biophys
Res Commun. 342:1228–1232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu TH, Raval A, Chen SS, Matkovic JJ,
Byrd JC and Plass C: CpG island methylation and expression of the
secreted frizzled-related protein gene family in chronic
lymphocytic leukemia. Cancer Res. 66:653–658. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yau TO, Chan CY, Chan KL, Lee MF, Wong CM,
Fan ST and Ng IO: HDPR1, a novel inhibitor of the WNT/beta-catenin
signaling, is frequently downregulated in hepatocellular carcinoma:
Involvement of methylation-mediated gene silencing. Oncogene.
24:1607–1614. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roman-Gomez J, Jimenez-Velasco A, Agirre
X, Castillejo JA, Navarro G, Barrios M, Andreu EJ, Prosper F,
Heiniger A and Torres A: Transcriptional silencing of the
Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute
lymphoblastic leukaemia. Br J Cancer. 91:707–713. 2004.PubMed/NCBI
|
|
21
|
Suzuki H, Watkins DN, Jair KW, Schuebel
KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van
Engeland M, et al: Epigenetic inactivation of SFRP genes allows
constitutive WNT signaling in colorectal cancer. Nat Genet.
36:417–422. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mazieres J, He B, You L, Xu Z, Lee AY,
Mikami I, Reguart N, Rosell R, McCormick F and Jablons DM: Wnt
inhibitory factor-1 is silenced by promoter hypermethylation in
human lung cancer. Cancer Res. 64:4717–4720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mori F, Strano S and Blandino G:
MicroRNA-181a/b: Novel biomarkers to stratify breast cancer
patients for PARPi treatment. Cell Cycle. 12:1823–1824. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Taylor MA, Sossey-Alaoui K, Thompson CL,
Danielpour D and Schiemann WP: TGF-β upregulates miR-181a
expression to promote breast cancer metastasis. J Clin Invest.
123:150–163. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bisso A, Faleschini M, Zampa F, Capaci V,
De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami
R, et al: Oncogenic miR-181a/b affect the DNA damage response in
aggressive breast cancer. Cell Cycle. 12:1679–1687. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jianwei Z, Fan L, Xiancheng L, Enzhong B,
Shuai L and Can L: MicroRNA 181a improves proliferation and
invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol.
34:3331–3337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishimura J, Handa R, Yamamoto H, Tanaka
F, Shibata K, Mimori K, Takemasa I, Mizushima T, Ikeda M, Sekimoto
M, et al: microRNA-181a is associated with poor prognosis of
colorectal cancer. Oncol Rep. 28:2221–2226. 2012.PubMed/NCBI
|
|
30
|
Zhang X, Nie Y, Du Y, Cao J, Shen B and Li
Y: MicroRNA-181a promotes gastric cancer by negatively regulating
tumor suppressor KLF6. Tumour Biol. 33:1589–1597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He Q, Zhou X, Li S, Jin Y, Chen Z, Chen D,
Cai Y, Liu Z, Zhao T and Wang A: MicroRNA-181a suppresses salivary
adenoid cystic carcinoma metastasis by targeting MAPK-Snai2
pathway. Biochim Biophys Acta. 1830:5258–5266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou JY, Ma WL, Fei J, Ding DP, Shi R,
Jiang L and Zheng WL: Effects of microRNA miR-181a on gene
expression profiles of K562 cells. Nan Fang Yi Ke Da Xue Xue Bao.
26:606–609. 2006.(In Chinese). PubMed/NCBI
|
|
33
|
Li Y, Kuscu C, Banach A, Zhang Q,
Pulkoski-Gross A, Kim D, Liu J, Roth E, Li E, Shroyer KR, et al:
miR-181a-5p inhibits cancer cell migration and angiogenesis via
downregulation of matrix metalloproteinase-14. Cancer Res.
75:2674–2685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shin KH, Bae SD, Hong HS, Kim RH, Kang MK
and Park NH: miR-181a shows tumor suppressive effect against oral
squamous cell carcinoma cells by downregulating K-ras. Biochem
Biophys Res Commun. 404:896–902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Debernardi S, Skoulakis S, Molloy G,
Chaplin T, Dixon-McIver A and Young BD: MicroRNA miR-181a
correlates with morphological sub-class of acute myeloid leukaemia
and the expression of its target genes in global genome-wide
analysis. Leukemia. 21:912–916. 2007.PubMed/NCBI
|
|
36
|
Pons A, Nomdedeu B, Navarro A, Gaya A, Gel
B, Diaz T, Valera S, Rozman M, Belkaid M, Montserrat E, et al:
Hematopoiesis-related microRNA expression in myelodysplastic
syndromes. Leuk Lymphoma. 50:1854–1859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et
al: MicroRNAs regulate critical genes associated with multiple
myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang
YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly
enhances drug sensitivity in chronic lymphocytic leukemia cells via
targeting multiple anti-apoptosis genes. Carcinogenesis.
33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Li Z, He C, Wang D, Yuan X, Chen J
and Jin J: MicroRNAs expression signatures are associated with
lineage and survival in acute leukemias. Blood Cells Mol Dis.
44:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roperch JP, Incitti R, Forbin S, Bard F,
Mansour H, Mesli F, Baumgaertner I, Brunetti F and Sobhani I:
Aberrant methylation of NPY, PENK, and WIF1 as a promising marker
for blood-based diagnosis of colorectal cancer. BMC Cancer.
13:5662013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Alvarez C, Tapia T, Cornejo V, Fernandez
W, Muñoz A, Camus M, Alvarez M, Devoto L and Carvallo P: Silencing
of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter
hypermethylation in hereditary breast cancer. Mol Carcinog.
52:475–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tang Y, Simoneau AR, Liao WX, Yi G, Hope
C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, et al: WIF1, a Wnt
pathway inhibitor, regulates SKP2 and c-myc expression leading to
G1 arrest and growth inhibition of human invasive urinary bladder
cancer cells. Mol Cancer Ther. 8:458–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nygren MK, Døsen-Dahl G, Stubberud H,
Wälchli S, Munthe E and Rian E: beta-catenin is involved in
N-cadherin-dependent adhesion, but not in canonical Wnt signaling
in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp
Hematol. 37:225–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shao N, Zou J, Li J, Chen F, Dai J, Qu X,
Sun X, Ma D and Ji C: Hyper-activation of WNT/β-catenin signaling
pathway mediates anti-tumor effects of histone deacetylase
inhibitors in acute T lymphoblastic leukemia. Leuk Lymphoma.
53:1769–1778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hsieh JC, Kodjabachian L, Rebbert ML,
Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB and Nathans J:
A new secreted protein that binds to Wnt proteins and inhibits
their activities. Nature. 398:431–436. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang
Z, Xi J, Yan L and Gu J: MicroRNA-181a promotes tumor growth and
liver metastasis in colorectal cancer by targeting the tumor
suppressor WIF-1. Mol Cancer. 13:862014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Willert K and Nusse R: Beta-catenin: A key
mediator of Wnt signaling. Curr Opin Genet Dev. 8:95–102. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
